维生素K拮抗剂与非维生素K拮抗剂口服抗凝药治疗肠系膜静脉血栓的临床结局比较
本研究在三级医院纳入2014年1月至2022年7月经CT诊断的肠系膜静脉血栓患者225例,其中44例接受超过3个月的长期抗凝治疗,分为维生素K拮抗剂组(21例)与非维生素K拮抗剂口服抗凝药组(23例)。两组均无肠系膜静脉血栓相关症状复发,血栓溶解率与出血并发症无临床显著差异;作者认为非维生素K拮抗剂口服抗凝药可考虑作为传统治疗的替代选择。
要点
- 两组均未观察到肠系膜静脉血栓相关症状复发。
- CT示完全溶解71%、部分溶解19%、无变化10%(P=.075)。
- 非维生素K拮抗剂组随访时间较短(中位57 vs 28个月,P=.048)。
核心结论
- 尽管非维生素K拮抗剂口服抗凝药组随访时间较短,其血栓溶解率与出血并发症与维生素K拮抗剂组相比无临床显著差异。
- 作者认为,尽管非维生素K拮抗剂口服抗凝药对患者的长期影响研究有限,非维生素K拮抗剂口服抗凝药可考虑作为传统治疗的替代选择。
研究设计与样本
- 2014年1月至2022年7月,在一家三级医院经CT诊断肠系膜静脉血栓225例。
- 其中44例接受超过3个月的长期抗凝治疗并纳入研究,按抗凝药分为维生素K拮抗剂组(第1组,n=21)与非维生素K拮抗剂口服抗凝药组(第2组,n=23)。
- 疗效结局为症状复发与随访CT示血栓溶解,安全性结局为出血并发症。
主要发现
- 患者中位年龄56岁(范围46-68岁),52%为男性。
- 最常见危险因素是腹腔内感染(30%)。
- 抗凝治疗中位时长13个月(第1组20个月 vs 第2组6个月;P=.076)。
- 44例中17例(39%)接受标准治疗。
- 第1组中位随访时间长于第2组(57 vs 28个月;P=.048)。
关键数值与推荐
- 两组均未观察到肠系膜静脉血栓相关症状复发。
- 随访CT中位随访时长31个月(第1组42个月 vs 第2组18个月;P=.064)。
- CT示完全血栓溶解、部分溶解、无变化分别为71%、19%、10%(P=.075)。
- 第2组2例发生静脉曲张出血和黑便,此后停止抗凝治疗。
临床怎么用
- 作者认为非维生素K拮抗剂口服抗凝药可考虑作为传统治疗的替代选择。
- 原文未据此给出其他推荐。
局限性
- 非维生素K拮抗剂口服抗凝药组随访时间较短。
- 原文指出非维生素K拮抗剂口服抗凝药对患者的长期影响研究有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Non-vitamin K antagonist oral anticoagulants have shown similar efficacy and lower bleeding rates than vitamin K antagonists for venous thromboembolism. However, this has not been proven in mesenteric vein thrombosis. This study aimed to compare the clinical outcomes of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. METHODS: Between January 2014 and July 2022, mesenteric vein thrombosis was diagnosed on computed tomography in 225 patients in a tertiary hospital. Among them, a total of 44 patients who underwent long-term anticoagulation therapy over 3 months were enrolled in this study. Patients were divided into two groups based on the anticoagulant used: vitamin K antagonists (Group 1, n = 21) and non-vitamin K antagonist oral anticoagulants (Group 2, n = 23). The efficacy outcomes were symptom recurrence and thrombus resolution on follow-up computed tomography, and the safety outcome was bleeding complications. RESULTS: The median age of the patients was 56 years (range, 46-68 years), and 52% were men. The most common risk factors were unprovoked intra-abdominal infections (30%). The median duration of anticoagulation therapy was 13 months (20 months in Group 1 vs 6 months in Group 2; P = .076). Of the 44 patients, 17 (39%) received the standard treatment. The median follow-up period was longer in Group 1 than in Group 2 (57 vs 28 months; P = .048). No recurrence of mesenteric vein thrombosis-related symptoms were observed in either group. The median duration of follow-up computed tomography was 31 months (42 months in Group 1 vs 18 months in Group 2; P = .064). Computed tomography revealed complete thrombus resolution, partial resolution, and no changes in 71%, 19%, and 10%, respectively (P = .075). Regarding bleeding complications, varix bleeding and melena developed in two patients in Group 2, and anticoagulation treatment thereafter ceased. CONCLUSIONS: Despite the short follow-up duration in the non-vitamin K antagonist oral anticoagulants group, there was no clinically significant difference in the thrombus resolution rate or bleeding complications when compared with the vitamin K antagonists group. Although research on the long-term effects of non-vitamin K antagonist oral anticoagulants in patients is limited, non-vitamin K antagonist oral anticoagulants can be considered an alternative to conventional treatments.
引用
- Kim YH, Kim HJ, Park S, et al. Comparing clinical outcomes of vitamin K antagonists vs non-vitamin K antagonists in anticoagulant therapy for mesenteric venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38754777. doi:10.1016/j.jvsv.2024.101903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。